PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 23, 2026International Journal of Molecular Sciences0 citationsOpen Access

Gut Microbiota and Type 2 Diabetes: Genetic Associations, Biological Mechanisms, Drug Repurposing, and Diagnostic Modeling

View Full Paper
XJXinqi JinXCXuanyi ChenHCHeshan Chen

Key Points

  • The research aims to understand the causal relationship between gut microbiota and type 2 diabetes (T2D) and the underlying biological mechanisms.
  • Conducted a two-sample Mendelian randomization analysis to assess gut microbiota-T2D relationship.
  • Integrated genome-wide association studies and cis-eQTL data to identify key genes.
  • Employed network pharmacology to explore drug repurposing opportunities.
  • Analyzed gut microbiota community and developed diagnostic models using machine learning techniques.
  • Identified 17 gut microbiota taxa linked to T2D, with three taxa showing significant associations.
  • Ten key genes, including EXOC4 and IGF1R, were associated with T2D risk.
  • Developed a diagnostic model (XGBoost) with an AUC of 0.84, achieving high sensitivity and specificity.
  • Reduced α-diversity in T2D patients, and significant β-diversity differences were found.

Abstract

Gut microbiota is a potential therapeutic target for type 2 diabetes (T2D), but its role remains unclear. Investigating causal associations between them could further our understanding of their biological and clinical significance. A two-sample Mendelian randomization (MR) analysis was conducted to assess the causal relationship between gut microbiota and T2D. Key genes and mechanisms were identified through the integration of Genome-Wide Association Studies (GWAS) and cis-expression quantitative trait loci (cis-eQTL) data. Network pharmacology was applied to identify potential drugs and targets. Additionally, gut microbiota community analysis and machine learning models were used to construct a diagnostic model for T2D. MR analysis identified 17 gut microbiota taxa associated with T2D, with three showing significant associations: Actinomyces (odds ratio OR = 1.106; 95% confidence interval CI: 1.06–1.15; p < 0.01; adjusted p-value padj = 0.0003), Ruminococcaceae (UCG010 group) (OR = 0.897; 95% CI: 0.85–0.95; p < 0.01; padj = 0.018), and Deltaproteobacteria (OR = 1.072; 95% CI: 1.03–1.12; p < 0.01; padj = 0.029). Ten key genes, such as EXOC4 and IGF1R, were linked to T2D risk. Network pharmacology identified INSR and ESR1 as target driver genes, with drugs like Dienestrol showing promise. Gut microbiota analysis revealed reduced α-diversity in T2D patients (p < 0.05), and β-diversity showed microbial community differences (R2 = 0.012, p = 0.001). Furthermore, molecular docking confirmed the binding affinity of potential therapeutic agents to their targets. Finally, we developed a class-weight optimized Extreme Gradient Boosting (XGBoost) diagnostic model, which achieved an area under the curve (AUC) of 0.84 with balanced sensitivity (95.1%) and specificity (83.8%). Integrating machine learning predictions with MR causal inference highlighted Bacteroides as a key biomarker. Our findings elucidate the gut microbiota-T2D causal axis, identify therapeutic targets, and provide a robust tool for precision diagnosis.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Jin et al. (2026) studied this question.

synapsesocial.com/papers/69730f59c8125b09b0d1f228https://doi.org/10.3390/ijms27021070
Ask AI
Helpful
Bookmark
Share
View Full Paper